0001490953-23-000003.txt : 20230214 0001490953-23-000003.hdr.sgml : 20230214 20230214122349 ACCESSION NUMBER: 0001490953-23-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 504(b)(1) (not (i), (ii) or (iii)) ITEM INFORMATION: 06b FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 EFFECTIVENESS DATE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunophotonics, Inc. CENTRAL INDEX KEY: 0001490953 IRS NUMBER: 264471225 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-473411 FILM NUMBER: 23625493 BUSINESS ADDRESS: STREET 1: 4320 FOREST PARK AVENUE, #303 (BAL) CITY: ST. LOUIS STATE: MO ZIP: 63108 BUSINESS PHONE: 636-675-6161 MAIL ADDRESS: STREET 1: 4320 FOREST PARK AVENUE, #303 (BAL) CITY: ST. LOUIS STATE: MO ZIP: 63108 FORMER COMPANY: FORMER CONFORMED NAME: ImmunoPhotonics, Inc. DATE OF NAME CHANGE: 20100503 D 1 primary_doc.xml X0708 D LIVE 0001490953 Immunophotonics, Inc. 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 314-501-1919 DELAWARE ImmunoPhotonics, Inc. Corporation true Luciano Alleruzzo 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 Executive Officer Director Promoter CEO, Director, and co-founder Tomas Hode 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 Executive Officer Director Promoter Chief Innovation Officer, Director, and co-founder Bobby W. Sandage 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 Director Chairman of the Board Wei R. Chen 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 Director Promoter Board member and co-founder Charlie Bolten 4340 Duncan Ave., Suite 212 St. Louis, MO 63110 St. Louis MO MISSOURI 63110 Director Jonathan Knowles 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 Director Miguel Zubizarreta 4340 Duncan Ave. Suite 212 St. Louis MO MISSOURI 63110 Director Pharmaceuticals Decline to Disclose 04 06b false 2023-01-06 false true false 50000 6500000 3452576 3047424 Rolling closings ongoing as of date of filing. false 22 0 0 None. 0 A portion of the gross proceeds will be used for general working capital, which may include salary payments to executive officers. An estimate of such amount is unknown at this time. false Immunophotonics, Inc. /s/ Alexander Hurst Alexander Hurst Corporate Secretary, General Counsel, and VP of Operations 2023-02-14